Home > News > Recent cases

Warner Music and Sony Music v TuneIn [2019] EWHC 2923 (Ch)1 November 2019Robert Howe QC and Jaani Riordan appeared for the Defendant in an important test case concerning the scope of the right of communication to the public. The Claimants (Warner and Sony) were music labels who owned or licensed the copyright in numerous sound recordings. TuneIn was a platform offering a directory of hyperlinks to freely […]
Shanks v Unilever Plc & Ors23 October 2019In Shanks v Unilever, Lord Kitchin, giving the judgment of the Supreme Court, set aside the IPO hearing officer’s decision, upheld by Arnold J and the Court of Appeal, rejecting Prof Shanks’s claim for compensation from his employer, the research arm of Unilever, on grounds that patents for an electrochemical testing device he invented were […]
Glaxo Wellcome UK Ltd and Anor v Sandoz Ltd and ors [2019] EWHC 2545 (Ch)4 October 2019Martin Howe QC, Iona Berkeley and Ashton Chantrielle appeared for the First to Fifth Defendants (‘Sandoz’) in this lengthy passing off trial, concerning the colour and get-up of the Claimants’ Seretide combination inhaler, an extremely successful prescription only medication. The action was dismissed, and on 4th February 2020 the Court of Appeal (Floyd LJ) refused […]
Coloplast A/S v Salts Healthcare [2019] EWHC 1979 (Pat)30 September 2019Andrew Lykiardopoulos QC and Maxwell Keay appeared for the Claimant, Coloplast, to oppose an application brought by the Defendant to stay UK infringement and validity proceedings pending the conclusion of opposition proceedings at the European Patent Office. Applying the IPCom guidance, David Stone, siting as a Deputy High Court Judge, dismissed the stay application. Following […]
Pfizer v F. Hoffman La-Roche [2019] EWHC 1520 (Pat)20 September 2019Richard Meade QC and Thomas Jones  appeared for the Claimant, Pfizer, and Andrew Lykiardopoulos QC and Mark Chacksfield QC appeared for the Defendant, Roche, in a case concerning Arrow relief in circumstances where no UK Patent could grant by reason of dedesignations. The case concerned Pfizer’s proposed launch of a biosimilar containing bevacizumab to be […]